IDL Diagnostics (IDLDX) Q1 2026 earnings summary

Executive summary

• Achieved record Q1 performance with strong sales growth, profitability, and positive cash flow, supporting international expansion and product launches.

• Formed a joint venture with Concile GmbH to broaden the product portfolio and access new markets.

• CEO Anders Hultman announced his resignation after significant company growth and strategic milestones.

Financial highlights

• Net sales for Q1 2026 reached SEK 16,737 thousand, up from SEK 15,307 thousand year-over-year.

• Operating profit was SEK 1,222 thousand, compared to a loss of SEK -2,503 thousand in Q1 2025.

• EBITDA improved to SEK 2,158 thousand from SEK -1,609 thousand year-over-year.

• Gross margin increased to 65.6% from 53.0% in Q1 2025.

• Cash flow from operating activities was SEK 2,138 thousand, with cash and cash equivalents at SEK 37,334 thousand as of March 31, 2026.

Outlook and guidance

• Anticipates continued strong growth in the global cancer diagnostics market, with a projected CAGR of 6.0% through 2034.

• Focus remains on expanding in existing and new markets, launching new products, and leveraging biomarker-driven diagnostics.